Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Aspirin Use for Preeclampsia Prevention
2025-524646-94-00Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised trial of aspirin in preeclampsia (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Preterm preeclampsia incidence. Planned start Oct 2026; status: authorised.
02
Drugs
aspirin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on 2025-524646-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524646-94-00.